Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf(The Netherlands Cancer Institute), Peter Hohenberger(Heidelberg University), Patrick Schöffski(KU Leuven), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), M. Ouali(European Organisation for Research and Treatment of Cancer), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Corneel Coens(European Organisation for Research and Treatment of Cancer), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Ian Judson(Erasmus Hospital), Rachel Hodge(GlaxoSmithKline (United Kingdom)), Massimo Aglietta(Verizon (United States)), George D. Demetri(Dana-Farber Cancer Institute), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Yasuo Beppu(Tokyo National Hospital), Sant P. Chawla(Sarcoma Oncology Center), Arthur P. Staddon(University of Pennsylvania), Nobuhito Araki(Ashiya University), Dong‐Wan Kim(Seoul National University Hospital), Axel Le Cesne(Institut Gustave Roussy), Mohammed R Dewji(GlaxoSmithKline (United Kingdom)), B. Bui-Nguyen(Institut Bergonié)
Cited by 2,085
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k